Dupixent® ( dupilumab ) Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAI - Regeneron Pharmaceuticals ( NASDAQ:REGN )
TARRYTOWN, N.Y. and PARIS, Oct. 24, 2024 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc.
| Ticker |
Sentiment |
Impact |
|
REGN
|
Neutral
|
5 %
|
|
META
|
Neutral
|
1 %
|
|
SNY
|
Neutral
|
12 %
|
